| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 77.87 | 0.00 (0.00%) | 38.44 - 87.47 | 19.0 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 77.87 |
| Day's Range | -- - -- |
| Market Cap | 17.2B |
| Avg Volume (10 Day) | 1.8M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -2.36 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Vertex Completes Redemption of Convertible Senior Subordinated Notes
Business Wire - Tuesday 06/18/2013 8:30 AM ET
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals
PR Newswire - Tuesday 06/18/2013 8:00 AM ET
Vertex Announces Webcast of its Presentation at the Goldman Sachs 34th Annual Global Healthcare Conference
Business Wire - Wednesday 06/05/2013 5:30 PM ET
Vertex Announces Presentation of Data at European Cystic Fibrosis Society Conference
Business Wire - Wednesday 06/05/2013 10:21 AM ET
| VRTX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -20.22% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.99 | |
| LT Debt/Equity | 0.98 | |
| Earnings Yield | -- | |
| Price/Sales | 12.17 |
| Company | Last | Change |
|---|---|---|
| Alexion Pharmaceuticals Inc | 91.09 | 0.00% |
| Shire PLC | 96.71 | 0.00% |
| Regeneron Pharmaceuticals Inc | 231.38 | 0.00% |
| Illumina Inc | 70.40 | 0.00% |
| BioMarin Pharmaceutical Inc | 57.21 | 0.00% |
Data is delayed by at least 15 min.